

# TimothÃ© MÃ©nard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9357758/publications.pdf>

Version: 2024-02-01

17  
papers

109  
citations

1683934

5  
h-index

1474057

9  
g-index

23  
all docs

23  
docs citations

23  
times ranked

37  
citing authors

#	ARTICLE	IF	CITATIONS
1	Good quality practices for artificial intelligence in genetics. <i>European Journal of Human Genetics</i> , 2022, 30, 993-995.	1.4	2
2	Advanced analytics for clinical trial quality: Commentary on "Can quality management drive evidence generation?". <i>Clinical Trials</i> , 2022, , 174077452210789.	0.7	0
3	Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 433-441.	0.8	3
4	Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing: A Quality Assurance Strategy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
5	Follow-up on the Use of Advanced Analytics for Clinical Quality Assurance: Bootstrap Resampling to Enhance Detection of Adverse Event Under-Reporting. <i>Drug Safety</i> , 2021, 44, 121-123.	1.4	8
6	Using Statistical Modeling for Enhanced and Flexible Pharmacovigilance Audit Risk Assessment and Planning. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 190-196.	0.8	6
7	Letter to the Editor: New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 631-632.	0.8	7
8	Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1066-1074.	0.8	3
9	Clinical Quality in Cancer Research: Strategy to Assess Data Integrity of Germline Variants Inferred from Tumor-Only Testing Sequencing Data. <i>Pharmaceutical Medicine</i> , 2021, 35, 225-233.	1.0	1
10	Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 799-803.	1.3	9
11	Bayesian Modeling for the Detection of Adverse Events Underreporting in Clinical Trials. <i>Drug Safety</i> , 2021, 44, 949-955.	1.4	6
12	Open Source Analytics App for Clinical Trials: Letter to the Editor "A Novel App for Insights into Laboratory Data of Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1107-1108.	0.8	0
13	Correspondence on "Artificial intelligence"-assisted phenotype discovery of fragile X syndrome in a population-based sample-by Movaghar et al. <i>Genetics in Medicine</i> , 2021, , .	1.1	2
14	Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?. <i>Drug Safety</i> , 2020, 43, 295-296.	1.4	11
15	Leveraging analytics to assure quality during the Covid-19 pandemic - The COVACTA clinical study example. <i>Contemporary Clinical Trials Communications</i> , 2020, 20, 100662.	0.5	11
16	Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials?. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1227-1235.	0.8	11
17	Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning. <i>Drug Safety</i> , 2019, 42, 1045-1053.	1.4	26